Sequel Med Tech

Sequel Med Tech, founded in 2023 and based in Manchester, New Hampshire, is a healthcare technology company dedicated to improving diabetes management through innovative drug-delivery systems. Co-founded by Dean Kamen and others, the company focuses on integrating advanced technology with patient-centric design to simplify disease management. The company offers the twiist® Automated Insulin Delivery (AID) System, which is FDA-cleared and designed to enhance glucose control by automatically adjusting insulin delivery. Sequel has partnered with Senseonics to incorporate the Eversense 365 implantable continuous glucose monitor into its AID system, creating a unique solution that minimizes interruptions in diabetes management. Additionally, Sequel develops holistic disease management solutions, including customized insulin therapy and process innovations for pharmaceutical companies. Sequel Med Tech aims to enhance access to insulin therapy for healthcare providers, patients, employers, and health plans, while also collaborating with pharmaceutical companies to design user-friendly delivery mechanisms. The company's mission is to prioritize affordability and accessibility, ultimately improving the quality of life for individuals with diabetes.